Products - Pipeline
Cao Pharmaceuticals has designed next generation CPT derivatives that demonstrate increased activity in vitro of ten fold and even 100 fold compared to currently approved chemotherapy drugs. They are developing an improved design of a currently approved CPT based drug which should increase the activity and reduce the toxicity of the drug. These products will be screened and developed as pipeline products. Cao Pharmaceuticals will synthesize and develop these drugs in parallel to their lead drug CZ48.
The company's founder, Zhisong Cao, also holds the patient rights for a CPT drug that has demonstrated superior efficacy against a broad spectrum of cancers grown in nude mice. These cancers are listed in the table below. In sharp contrast to most chemotherapy drugs, this CPT based drug has shown almost no detectable toxicity in the nude mouse growing these human tumors.
Total inhibition seen by oral administration in 28 out of 29 tumor types (specified below). Note: Desmoplastic small round cell tumor (DSRCT) is an aggressive and rare cancer that primarily occurs as masses in the abdomen (although it may occur in other areas). It is considered a childhood cancer, although occasionally occurring in adults, and predominantly strikes young adolescent boys in a higher rate than adolescent girls. Because the number of new cases per year is relatively small, little research is done on this form of cancer. We are excited that this drug, along with several other CPT based drugs, appear to offer some hope for these individuals and their families.